Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 14/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 14/20 | 1.00 |
| ▸ | CDK2 | P24941 | 14/20 | 1.00 |
| ▸ | GSK3A | P49840 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29733651 | 1.00 | GSK3B (1.00) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| Hydrochloric Acid SCHEMBL6035107 | 0.99 | GSK3B (0.98) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| Hydrochloric Acid SCHEMBL6606349 | 0.99 | GSK3B (0.98) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL3331512 | 0.97 | GSK3B (0.93) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| Hydrochloric Acid SCHEMBL6034735 | 0.96 | GSK3B (0.92) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL6034983 | 0.92 | GSK3B (1.00) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL6034852 | 0.91 | GSK3B (0.84) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL6034189 | 0.91 | GSK3B (1.00) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| Hydrochloric Acid SCHEMBL6035095 | 0.91 | GSK3B (0.98) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL3332447 | 0.91 | GSK3B (0.83) | GSK3BCCNE2CCNE1CDK2GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 581 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070916-A | Application of arteannuin with double functions in promoting liver cell maturation and relieving liver lipid metabolism dysfunction | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | 2026-05-22 | — | — | CN | claimed |
| WO-2026103625-A1 | METHOD FOR CONSTRUCTING THYMUS ORGANOID AND USE THEREOF | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | 2026-05-21 | — | — | WO | claimed |
| WO-2025251988-A9 | REAGENT COMBINATION OR KIT FOR CONSTRUCTING EMBRYOID AND USE THEREOF | 广州国家实验室 | 2026-05-15 | — | — | WO | claimed |
| US-20260132380-A1 | Hepatocyte Expansion Methods | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2026-05-14 | — | — | US | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-12618045-B2 | Automated method for preparing retinal pigment epithelium cells | CENTRE D'ETUDE DES CELLULES SOUCHES (CECS) (FR) | 2026-05-05 | — | — | US | claimed |
| US-20260108514-A1 | METHOD OF INHIBITING EPITHELIAL-MESENCHYMAL TRANSITION AND CANCER METASTASIS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2026-04-23 | — | — | US | claimed |
| EP-4720261-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | University of Southern California (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4713433-A2 | LIVER ORGANOIDS WITH INTRAHEPATIC SYMPATHETIC NERVES, AND METHODS OF USE THEREOF | Children's Hospital Medical Center (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4689067-A2 | CLINICAL-GRADE ORGANOIDS | Children's Hospital Medical Center (US) | 2026-02-11 | — | — | EP | claimed |
| US-10195284-B2 | Compositions and methods for controlled localized delivery of bone forming therapeutic agents | UNIVERSITY OF ROCHESTER (US) | 2019-02-05 | — | — | US | claimed |
| US-20170072062-A1 | Compositions and Methods for Controlled Localized Delivery of Bone Forming Therapeutic Agents | UNIVERSITY OF ROCHESTER | 2017-03-16 | — | — | US | claimed |
| US-7576093-B2 | Method of treatment of bone-related disorders or conditions | ASTRAZENECA AB (SE) | 2009-08-18 | — | — | US | claimed |
| CN-101394851-A | Gsk-3 inhibitors for the treatment of osteoporosis | ASTRAZENECA AB (SE) | 2009-03-25 | — | — | CN | claimed |
| EP-1993550-A1 | GSK-3 INHIBITORS FOR THE TREATMENT OF OSTEOPOROSIS | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | claimed |
| US-20070213322-A1 | Administering 3-amino-6-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-pyridin-3-ylpyrazine-2-carboxamide; glycogen synthase kinase-3-beta inhibitor; osteoporosis; osteogenesis; increased cancellous bone; increased bone mineral density; strenthening to reduce breakage;enhanced fracture healing | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | US | claimed |
| WO-2007102770-A1 | GSK-3 INHIBITORS FOR THE TREATMENT OF OSTEOPOROSIS | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | WO | claimed |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | claimed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | claimed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108514-A1 | METHOD OF INHIBITING EPITHELIAL-MESENCHYMAL TRANSITION AND CANCER METASTASIS | HDAC5, HDAC6, GSK3B | GSK3B 3/4885CCNE2 4530/4885CCNE1 2848/4885 |
| US-12618045-B2 | Automated method for preparing retinal pigment epithelium cells | WNT3A, BRSK1, BMP2K | GSK3B 16/4885CCNE2 889/4885CCNE1 569/4885 |
| US-20070213322-A1 | Administering 3-amino-6-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-pyridin-3-ylpyrazine-2-carboxamide; glycogen synthase kinase-3-beta inhibitor; osteoporosis; osteogenesis; increased cancellous bone; increased bone mineral density; strenthening to reduce breakage;enhanced fracture healing | GSK3B, GSK3A, STK3 | GSK3B 1/4885CCNE2 3350/4885CCNE1 2693/4885 |
| US-20260132380-A1 | Hepatocyte Expansion Methods | HGF, CTNND1, MET | GSK3B 8/4885CCNE2 845/4885CCNE1 266/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | GSK3B 2/4885CCNE2 792/4885CCNE1 407/4885 |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | GSK3A, GSK3B, PYGL | GSK3B 2/4885CCNE2 438/4885CCNE1 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.